The strains used in the experiments (listed in Supplementary Table 2 ) were grown
as described previously 9 (link). The
OKF6/TERT-2 oral epithelial cell line (provided by Jim Rheinwald,
Dana-Farber/Harvard Cancer Center, Boston, MA) 29 (link) was grown as described 9 (link),29 (link). OKF6/TERT-2 cells have been authenticated by
RNA-Seq3 (link), and have been
tested for mycoplasma contamination. To determine the effects of the various
inhibitors, the host cells were treated for 1 h prior to stimulation or
infection with 2.5 μM dasatinib 30 (link), 400 μM EphA2 antagonist, a
2,5-dimethylpyrrolyl benzoic acid derivative 15 (link),31 (link), 50 μM Stat3 inhibitor S31-201 32 (link), 1μM gefitinib 16 , 3 μg/ml dectin-1 mAb
(R&D Systems) 33 . In other
experiments, the cells were stimulated with 50 μg/ml depleted zymosan
(InvivoGen), 50 μg/ml mannan (Sigma), or 50 μg/ml laminarin
(InvivoGen). To deplete the OKF6/TERT-2 cells of EphA2, they were transfected
with random control siRNA (Santa Cruz Biotechnology; sc-37007), EphA2 siRNA
(Santa Cruz Biotechnology; sc-29304), or EphB2 siRNA (Santa Cruz Biotechnology;
sc-39949) with Lipofectamine 2000 (Invitrogen) following the
manufacturer’s instructions as described previously16 .
as described previously 9 (link). The
OKF6/TERT-2 oral epithelial cell line (provided by Jim Rheinwald,
Dana-Farber/Harvard Cancer Center, Boston, MA) 29 (link) was grown as described 9 (link),29 (link). OKF6/TERT-2 cells have been authenticated by
RNA-Seq3 (link), and have been
tested for mycoplasma contamination. To determine the effects of the various
inhibitors, the host cells were treated for 1 h prior to stimulation or
infection with 2.5 μM dasatinib 30 (link), 400 μM EphA2 antagonist, a
2,5-dimethylpyrrolyl benzoic acid derivative 15 (link),31 (link), 50 μM Stat3 inhibitor S31-201 32 (link), 1μM gefitinib 16 , 3 μg/ml dectin-1 mAb
(R&D Systems) 33 . In other
experiments, the cells were stimulated with 50 μg/ml depleted zymosan
(InvivoGen), 50 μg/ml mannan (Sigma), or 50 μg/ml laminarin
(InvivoGen). To deplete the OKF6/TERT-2 cells of EphA2, they were transfected
with random control siRNA (Santa Cruz Biotechnology; sc-37007), EphA2 siRNA
(Santa Cruz Biotechnology; sc-29304), or EphB2 siRNA (Santa Cruz Biotechnology;
sc-39949) with Lipofectamine 2000 (Invitrogen) following the
manufacturer’s instructions as described previously16 .